Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

BACKGROUND: Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related death and represents a major health burden worldwide. Current therapies for NSCLC include chemotherapy, immunotherapy, and targeted molecular agents such as tyrosine kinase inhibitors and epigenetic drugs such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Dominici, Claudia, Sgarioto, Nicolas, Yu, Zhenbao, Sesma-Sanz, Laura, Masson, Jean-Yves, Richard, Stéphane, Raynal, Noël J.-M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948358/
https://www.ncbi.nlm.nih.gov/pubmed/33691794
http://dx.doi.org/10.1186/s13148-021-01037-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948358/
https://www.ncbi.nlm.nih.gov/pubmed/33691794
http://dx.doi.org/10.1186/s13148-021-01037-1

Ejemplares similares